The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements

Entrectinib is an inhibitor of the tyrosine kinases TRKA, TRKB, TRKC [all together known as neurotrophic tyrosine receptor kinases (NTRKs)], ROS1 and anaplastic lymphoma kinase (ALK). On 31 July 2020, a conditional marketing authorisation valid through the European Union (EU) was issued for entrecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado, J., Pean, E., Melchiorri, D., Migali, C., Josephson, F., Enzmann, H., Pignatti, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988279/
https://www.ncbi.nlm.nih.gov/pubmed/33735800
http://dx.doi.org/10.1016/j.esmoop.2021.100087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988279/
https://www.ncbi.nlm.nih.gov/pubmed/33735800
http://dx.doi.org/10.1016/j.esmoop.2021.100087

Ejemplares similares